Trials in the Key of G: Building Level 1 Evidence on the Real-world Effectiveness of Prostate Biomarkers
- PMID: 35963777
- PMCID: PMC10566568
- DOI: 10.1016/j.euf.2022.08.001
Trials in the Key of G: Building Level 1 Evidence on the Real-world Effectiveness of Prostate Biomarkers
Abstract
A number of genomic classifiers are available to aid in shared decision-making for men with localized prostate cancer; however, there is no high-level evidence assessing their clinical utility. The two randomized controlled trials in this report prospectively evaluate the use of gene expression classifier testing at the time of cancer diagnosis and after surgical treatment.
Copyright © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Figures
References
-
- Hayes DF, Defining Clinical Utility of Tumor Biomarker Tests: A Clinician’s Viewpoint. J Clin Oncol, 2021. 39(3): p. 238–248. - PubMed
-
- Sargent DJ, et al., Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol, 2005. 23(9): p. 2020–7. - PubMed
-
- AskMUSIC Risk Calculator. 5/2/2022]; Available from: https://askmusic.med.umich.edu/tools/prostate-cancer-treatment-options.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
